Leuprolide
Get a source-linked, educational explanation from this profile.
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Leuprolide is listed as oncology / gnrh agonist.
- •Prostate Cancer
- •Endometriosis
- •Precocious Puberty
Regulatory status: FDA-Approved Rx.
Structure & Properties
Compound: Leuprolide; also known as Lupron, Eligard.
Pharmacologic class: Oncology / GnRH Agonist.
Known delivery routes: Subcutaneous, Intramuscular.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
GnRH receptor agonist — paradoxical downregulation with continuous use suppresses LH/FSH → hypogonadism.
- •Effective androgen/estrogen suppression
- •Tumor regression in hormone-sensitive prostate cancer
- •Endometriosis pain control
Human Research
Evidence grade: Clinical RCT (Phase III)
Clinical RCT (Phase III). Phase III TAP trials.
Laboratory Research
Phase III TAP trials
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Depot IM monthly or every 3/4/6 months. Same day of cycle.
Potential interactions and combinations to avoid
- •Pregnancy — contraindicated
- •Concurrent hormone therapy without oncology guidance
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Bone density loss
- •CV risk
- •Hot flashes
- •Tumor flare initially
- •Mood effects
Contraindications
- •Pregnancy
- •Undiagnosed abnormal vaginal bleeding
- •Hypersensitivity
- •Hormone-sensitive cancer (prostate, breast, ovarian, uterine) without oncology direction
- •Undiagnosed abnormal uterine or vaginal bleeding
- •Pregnancy or possible pregnancy (fetal harm / ovarian hyperstimulation risk)
- •Precocious puberty or unresolved pituitary pathology
- •History of thromboembolism or ovarian hyperstimulation syndrome
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: 3.75–22.5 mg depot (1–6 month)
Frequency: Monthly to every 6 months
Cycling: Depot dosing on schedule; no cycling.
Depot IM
Prostate cancer, endometriosis, precocious puberty.
Depot syringe (Lupron Depot) 1, 3, 4, or 6 month. Reconstitute with supplied diluent; deep IM gluteal, rotate side each cycle.
Subcutaneous
Daily formulation (rarely used now).
Insulin syringe. Abdomen SubQ.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Add-back therapy for endometriosis; standard oncology regimens
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
What is Leuprolide?
In plain words
Leuprolide is a prescription medicine that acts like a hormone controlling sex hormone production. It first stimulates this system, but continued exposure lowers sex hormone levels. It is studied and approved for prostate cancer, endometriosis, and puberty that starts too early. Clinical trials support its use, but risks include bone loss, heart and blood vessel problems, hot flashes, and an early worsening of tumor symptoms.
Technical definition
Leuprolide (Lupron, Eligard) is a synthetic peptide analogue of gonadotropin-releasing hormone (GnRH) and a GnRH receptor agonist. Continuous exposure paradoxically downregulates receptor signaling, suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and producing hypogonadism. It is an FDA-approved prescription drug for prostate cancer, endometriosis, and precocious puberty, with Phase III randomized controlled trial evidence; risks include bone density loss, cardiovascular risk, hot flashes, and initial tumor flare.
Function
Dosing
Recommended Time of Day
Any consistent time — depot injection per prescribed schedule.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Dorsogluteal (upper outer) — Upper outer quadrant of the buttock. Used for depot IM; alternate sides each cycle.
- Ventrogluteal — Palm on greater trochanter, index to ASIS — inject in the V. Safest IM site.
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Depot dosing on schedule; no cycling.
Timing & Interactions
- ·Pregnancy — contraindicated
- ·Concurrent hormone therapy without oncology guidance
- ·Add-back therapy for endometriosis; standard oncology regimens
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Leuprolide and sync them to Vial Lab.
Benefits
- ·Effective androgen/estrogen suppression
- ·Tumor regression in hormone-sensitive prostate cancer
- ·Endometriosis pain control
Risks
- ·Bone density loss
- ·CV risk
- ·Hot flashes
- ·Tumor flare initially
- ·Mood effects
Contraindications
- ·Pregnancy
- ·Undiagnosed abnormal vaginal bleeding
- ·Hypersensitivity
- ·Hormone-sensitive cancer (prostate, breast, ovarian, uterine) without oncology direction
- ·Undiagnosed abnormal uterine or vaginal bleeding
- ·Pregnancy or possible pregnancy (fetal harm / ovarian hyperstimulation risk)
- ·Precocious puberty or unresolved pituitary pathology
- ·History of thromboembolism or ovarian hyperstimulation syndrome
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
FDA-Approved Rx
Veterinary Use (Pets)
No established veterinary protocol for Leuprolide. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.